ArticleHereditas2025
A comprehensive in silico and invitro analysis revealed the diagnostic, prognostic and therapeutic potential of GNAI family genes in colon adenocarcinoma (COAD).
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGuanine nucleotide-binding protein alpha inhibiting activity polypeptides (GNAI1, GNAI2, and GNAI3) play critical roles in cell cycle regulation, intracellular signaling, and immune modulation. However, their contribution to colorectal adenocarcinoma (COAD) pathogenesis remains poorly defined. This study aimed to comprehensively evaluate the diagnostic, prognostic, and therapeutic relevance of GNAI genes in COAD through integrated in silico and in vitro analyses.
methodsmRNA and protein expression profiles of GNAI1, GNAI2, and GNAI3 were analyzed using TCGA, OncoDB, HPA databases, and RT-qPCR analysis across COAD cell lines. Genetic and epigenetic alterations were assessed using UALCAN, cBioPortal, and GSCA databases. Prognostic significance was evaluated through Kaplan–Meier survival and GENT2 databases. Potential miRNA regulators were identified via TargetScan and quantified using TaqMan assays. Immune interactions, immune infiltration, and drug sensitivity were examined using TISIDB and GSCA platforms. Functional effects of GNAI1 and GNAI2 overexpression were tested in SW480 and HCT116 cell lines using proliferation, colony formation, and wound healing assays.
resultsGNAI1, GNAI2, and GNAI3 were significantly downregulated in both COAD tissues and cell lines. This downregulation correlated with promoter hypermethylation, CNV deletions, and reduced patient survival. ROC analysis indicated better diagnostic potential, particularly for GNAI2 (AUC = 0.83). Pathway analysis revealed suppression of DNA damage and cell cycle regulatory pathways and activation of EMT-related signaling. Upregulated miRNAs—hsa-miR-133a-3p-1, hsa-miR-138-5p, and hsa-miR-141-3p—were identified as direct regulators, exhibiting strong diagnostic capacity. Immune profiling showed that GNAI genes were differentially expressed across immune subtypes, negatively correlated with immune inhibitors, and positively associated with stimulators. Overexpression of GNAI1 and GNAI2 significantly inhibited COAD cell proliferation, clonogenic potential, and migration.
conclusionThis study reveals the tumor-suppressive function of GNAI1, GNAI2, and GNAI3 in COAD through genetic, epigenetic, and miRNA-mediated regulation. Their downregulation is associated with poor prognosis, altered immune landscape, and therapy resistance. Restoration of GNAI function represents a promising avenue for diagnostic and therapeutic intervention in colorectal cancer. CLINICAL TRIAL NUMBER: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.